Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 19/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.58 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL541562 | 0.91 | CNR2 (0.64) | CNR2CYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL15397178 | 0.88 | CNR2 (0.60) | CNR2CYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL541772 | 0.81 | GSK3A (0.43) | GSK3AGSK3B | |
| SCHEMBL12796010 | 0.81 | GSK3A (0.49) | CNR2GSK3AGSK3B | |
| SCHEMBL12796008 | 0.78 | GSK3A (0.47) | GSK3AGSK3B | |
| SCHEMBL541606 | 0.77 | CNR2 (0.62) | CNR2CYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL541605 | 0.77 | CNR2 (0.62) | CNR2CYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL4419263 | 0.76 | CNR2 (0.82) | CNR2CYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL10145915 | 0.76 | CNR2 (0.44) | CNR2CYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL6526718 | 0.76 | GSK3A (0.43) | GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310373-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-21 | — | — | US | disclosed |
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
| WO-2010113834-A1 | PYRIMIDINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053912-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | CNR2 1/4885CYP1A2 1037/4885CYP2C19 1513/4885 |
| US-20130310373-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | CNR2 1/4885CYP1A2 991/4885CYP2C19 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.